Source file signed link, expires in 15 minutes
Extracted text 21
Page 1
[Organon] Proprietary Public Expose PT Organon Pharma Indonesia, Tbk October 21st ,2025
Page 2
[Organon] Proprietary
Agenda
Business Organization Sustainability Financial
Overview Structure Strategy- ESG Performance
2
Page 3
[Organon] Proprietary
Business Overview
3
Page 4
[Organon] Proprietary
4
Page 5
[Organon] Proprietary
Business Overview – Areas of Focus
Women’s Established
Biosimilar
Health Brands
Through our pipeline and portfolio, Our approach to biosimilars is Our established brands span a
we are working to deliver medicines focused on providing more range of therapeutic areas,
and devices that advance the accessible treatment options to including cardiovascular disease,
health of women through all stages patients, providers, and healthcare respiratory conditions, dermatology,
of her life journey. We focus on systems central nervous system disorders,
conditions that are unique to bone health, immunology, non-
women, affect her opioid pain management,
disproportionately or impact her menopause, and more..
differently, including fertility and
contraception, maternal health
conditions, and vaginal health.
5
Page 6
[Organon] Proprietary
AP Cluster
Indonesia, with its growing population, is now
the 4th most populous country in the world
and the 2nd most populous in the AP Cluster
after India, which has 1.45 billion people.
As part of the Organon AP Cluster, Indonesia
holds significant potential to grow in
alignment with Organon’s vision: “to give a
better and healthier every day for every
woman.”
Indonesia also plays a pivotal role in Organon’s
manufacturing network. Notably, the Pandaan
site in Indonesia stands as the only
manufacturing facility in the AP Cluster
Population : 284 Mil with 52% Males
48% Female
Land Size 1,904,569 km2
GDP Growth Rate: 5.2% ~
GDP Per Capita : 4.94 K USD
6
Page 7
[Organon] Proprietary
Company Strategies
The Company has established several strategies :
• Absorb increasing demand without any supply issue, through optimizing raw
material supplies
• Cost efficiency through optimization and systemization process, while also
increasing the number of QA specialties
• Increased accuracy and efficiency of the import export process
• Simplification of the data reporting process, leading to better and faster
regulatory compliance
7
Page 8
[Organon] Proprietary
Communication Strategies – CV
1. Enhancing Dyslipidemia Management
Communication Tactics:
• Utilize the updated lipid treatment guideline that can help standardize care to improve the patient's
quality of life.
• Partner with medical societies for symposiums or workshop discussions on ASCVD awareness.
• Develop a targeted digital campaign (webinars, emailers) to highlight LDL-C reduction’s link to Major
Adverse Cardiovascular Events (MACE) prevention.
2. Promoting Fixed Dose Combination (FDC)
Communication Tactics:
• Publish articles in medical journals to establish thought leadership.
• Create educational materials like brochures and explainer videos for HCPs.
• Highlighting the value of FDC over high-dose statin monotherapy in high-risk / very high-risk patients
8
Page 9
[Organon] Proprietary
Communication Strategies – WH
1. Advancing Contraceptive Implant Adoption
Communication Tactics:
• Launch for HCPs, focusing on technical training and Q&A sessions about implants.
• Create a robust knowledge resources and share through medical community channels.
• Showcase success stories from both patients and healthcare providers to build trust.
2. Supporting Government Partnerships for LARCs
Key Messages:
• Demonstrate Organon’s commitment to women’s health by emphasizing affordable access and training
support through BKKBN initiatives.
• Align messaging with Indonesia Family Planning 2030 program to gain buy-in from policymakers.
Communication Tactics:
• Develop a press release campaign celebrating Organon’s collaboration with BKKBN.
• Organize government roundtables to highlight the impact of Organon One Rod Implant in achieving
family planning goals.
9
Page 10
[Organon] Proprietary
Pandaan 50th Anniversary (1975 – 2025)
Milestones: Goals:
Employee Cross- Strengthen
Engagement & Functional Community
Wellbeing Collaboration Relationships
1975 - 1990 1990 - 2009 2009 - 2021
PT Essex PT Schering PT Merck
Indonesia Plough Sharp Dohme Employee Organon Science
Indonesia, Tbk. Pharma Media Handling
Gathering & Team Awards
Indonesia, Tbk.
Building Social Outreach Health Check-up
IWD & HER Day Program for Karangjati
Celebration Residents
US Consulate
2021 - present General visit to
PT Organon Pharma Indonesia, Tbk. OMS Pandaan
20 Aug 2025
10
Page 11
[Organon] Proprietary
Pandaan 50th Anniversary
11
Page 12
[Organon] Proprietary
Donation 1,000 units implants
We committed to contributes to family planning through collaborations with various stakeholders
Objective:
Celebrating World Contraception Day 2025 & part activities of 50 years Anniversary of Organon Manufacturing Site Pandaan
and to support provision of modern contraceptive as the government commitment on Family Planning 2030
Donation recipients :
Indonesian Midwives Association (PP IBI) – Jakarta & Surabaya selected as the insertion points
Key Timelines:
7 Oct – Donation ceremony handover to Indonesian Midwives Association
13 Oct – Jakarta midwivesa training & distribution
18 Oct – Surabaya midwivesa training & distribution
Oct- Jan – Implant insertion to patientsb and monthly monitoringc &
evaluation reported to Indonesian FDAd
Stakeholders:
aDonation notification required documents: Letter of Agreement, donation plan, handover report, distribution report, stock report
a Selected midwives that responsible for the insertion in Jakarta & Surabaya
b Based on eligible criteria from the BKKBN (Family Planning Government Body) and documented properly receiving the products for free
c Monthly monitoring including stock report and adverse events report if occur from the midwives to Head of Indonesian Midwives Association Branch Jakarta & Surabaya and Organon PIC to submit the report to dpoc
d Evaluation of the program including distribution, stock, feedback from the patients & midwives
Page 13
[Organon] Proprietary
Media exposure of donation 1,000 units implants
liputan6.com
KB Implan: Ukuran Sekecil
Korek Api, Manfaat Besar
untuk Cegah Kehamilan
Bertahun-Tahun - Health
Liputan6.com
JPNN.com
Dukung Program Nasional, Organon Indonesia
Donasikan 1.000 KB Implan Surya.co.id
Hari Kontrasepsi Sedunia Organon Indonesia
momsmoney.kontan.co.id Donasikan 1000 Unit KB Implan Ke PP IBI -
Surya.co.id
Makin Diminati, Ini Alasan KB Implan Cocok untuk Wanita
Modern
Cara Kerja KB Implan, Solusi Kontrasepsi
Sindonews Organon Indonesia Donasikan
Modern yang Efektif dan Aman untuk
Hari Kontrasepsi Sedunia, Organon Indonesia 1.000 unit KB Implan untuk
Keluarga
Donasikan 1.000 Unit KB Implan ke IBI 13 Program Keluarga
Dukung
Organon Donasikan 1.000 Unit KB
Berencana Nasional - Ayo
Implan untuk Dukung Kesehatan
Indonesia
Reproduksi Wanita Indonesia -
Page 14
[Organon] Proprietary
Organization Structure
Rapat Umum Pemegang Saham
General Meeting of Sharefolders Komite Audit
Audit Committee
Dewan Komisaris
Board of Commissionaires Ketua Chairman :
Edward Tanujaya
Presiden Komisaris
President of Commissionaire Anggota Members:
Andreas Daugaard Joergensen • Machmudin Eka P
Komisaris Komisaris Independen • Christine Tjen
Commissionaire Independent Commissionaire
Erwin Agung Edward Tanujaya
Direksi
Directors
Sekretaris Perusahaan
Presiden Direktur Corporate Secretary
President Director
Daniel Arie Noviandari
Direktur Direktur Direktur
Director Director Director
Yohanes Indrayana Andri Soelastyo Alison Yeap
14
Page 15
[Organon] Proprietary
ESG
Framework
15
Page 16
[Organon] Proprietary
Environmental Sustainability Goal
2050 ambitious environmental target
16
Page 17
[Organon] Proprietary
ENVIRONMENT Near-Term Goals and Long-Term Ambitions
GHG Emissions Water Materials
Integrate Circular Economy
Long- Term
Integrate Water Stewardship
Ambitions
principles into our business models
Net Zero Emissions principles into our business to maximize resource efficiency
models
• By 2025, we will reduce our Scope 1 and 2 • By 2025, we will reduce water usage in our • By 2025, >80% (range 80%-95%) of our
GHG emissions by >25% (range 25%- 40%) operations by >5% (range 5% -15%) from sites' operational waste will be reused,
from adjusted 2020* levels. adjusted 2020* levels. recycled or otherwise used beneficially.
• By 2023, we will characterize our Scope 3 • By 2023, we will characterize the water usage • By 2022, we will have developed Organon’s
Near-Term Goals
emissions. of our value chain. Sustainability Packaging guidelines, which will
• By 2025, >70% (range 70% - 90%) of our • By 2025, >70% (range 70% - 90%) of our drive recycled content, recyclability, and
overall spending will be with suppliers that overall spending will be with suppliers that responsible sourcing.
have GHG emission reduction programs. have water reduction programs. • From 2023, the packaging of all new products
will be designed according to Organon’s
Sustainable Packaging guidelines.
• By 2025, 30% of Organon’s legacy packaging
will be reviewed against the Organon
Sustainable Packaging guidelines to identify
opportunities to reduce environmental impact.
*Baseline will be adjusted to normal (non-covid) circumstances
17
Page 18
[Organon] Proprietary
Page 19
[Organon] Proprietary
2025 Performance Highlight
19
Page 20
[Organon] Proprietary
2025 Financial Position (YTM Sep’25 vs 2024)
20
Page 21
Thank you
Names mentioned 6 people and organisations named in the text · linked when the evidence is strong
unresolved
org
PT Essex
p.10
unresolved
org
PT Schering
p.10
unresolved
org
PT Merck Indonesia
p.10
Extraction attempts how the parser did, and what it refused
Nothing structured was extracted from this document — the attempts below say why.
No extraction attempted yet.